Aims: Iron reduction has been proposed as treatment for dysmetabolic iron overload syndrome (DIOS) and non-alcoholic fatty liver disease (NAFLD), but results of published trials are conflicting. We undertook a systematic review and meta-analysis to determine the impact of phlebotomy in DIOS and NAFLD.
INTRODUCTION

S EVERAL EPIDEMIOLOGICAL STUDIES have shown
an association between elevated body iron stores and insulin resistance, but a causal relationship between these has not been clearly established. The dysmetabolic iron overload syndrome (DIOS) was originally described as a form of mild iron overload associated with one or more features of the metabolic syndrome. 1 Although a majority of patients with DIOS have non-alcoholic fatty liver disease (NAFLD), fatty liver is not universally present in this condition. 2, 3 Conversely, NAFLD, which is also a manifestation of insulin resistance and the metabolic syndrome, is commonly but not invariably accompanied by evidence of expanded body iron stores. These observations suggest that DIOS and NAFLD are related conditions on a spectrum that links insulin resistance and disturbances in iron metabolism.
Collectively, these disorders and their related conditions represent serious global health concerns. Non-alcoholic fatty liver disease and its more aggressive form, non-alcoholic steatohepatitis (NASH), are associated with increased morbidity and overall mortality over matched population controls. 4, 5 The estimated prevalence of NAFLD varies from 20-50% worldwide. [5] [6] [7] The prevalence of NAFLD exceeds 60% in patients with diabetes mellitus, and is seen in more than 90% in patients undergoing bariatric surgery. Over time, NASH progresses to cirrhosis in a minority of patients. 6, 8 Liver transplantation is increasingly carried out in patients with cirrhosis from NASH. 8, 9 Lifestyle changes (LSC) to promote weight loss (i.e., diet and exercise) are the keystone in the management of NAFLD and can lead to histologic resolution; however, weight loss and its maintenance are challenges for many patients. 10 Unfortunately, safe and effective pharmacologic treatments for NAFLD are lacking. Thus, the development of alternative treatment strategies to decrease overall morbidity and mortality from NAFLD are urgently needed.
Oxidative stress has been implicated in the pathogenesis of DIOS and NASH (the second hit of the so-called "two hit" hypothesis), as it is thought to promote the development of insulin resistance and hepatocellular inflammation. 11 These observations suggest that interventions that mitigate oxidative stress could be a rational therapeutic approach for the treatment of NAFLD and DIOS. A potential source of oxidative stress in these patients is dysregulation of iron metabolism. As outlined above, DIOS is characterized by mild increases in body iron stores. Elevated serum ferritin levels are seen in up to 60% of patients with NASH, with increases in hepatic iron content occurring less commonly. [12] [13] [14] The relationship between dysregulated iron metabolism and NAFLD has been the subject of particular interest because of studies linking excess iron to advanced fibrosis and hepatocellular carcinoma in this condition. 12, 13, 15, 16 Furthermore, a recent 16-year follow-up study has shown that elevated ferritin levels in patients with NAFLD are associated with increased all-cause mortality. 17 These observations support the concept that iron reduction by means of phlebotomy might be of benefit in the treatment of NAFLD and DIOS.
In considering potential treatments for NAFLD and DIOS, phlebotomy is an attractive option, as it is very simple, easy to perform and inexpensive with minimal adverse events. It remains to be determined, however, whether iron reduction is beneficial in this context as several trials of phlebotomy in patients with NAFLD and DIOS have yielded inconsistent results. The aim of the current study was to undertake a systematic review and meta-analysis of trials that have evaluated the effect of phlebotomy on indices of insulin resistance and liver biochemistries in patients with DIOS and/or NAFLD.
METHODS
W
E CARRIED OUT the systematic review and the meta-analysis as per the guidance provided by the Cochrane handbook. We reported using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The criteria for study selection, methodology, and analysis were determined a priori.
Selection of studies
We undertook a systematic search of PubMed (Medline) and Scopus databases up to 31 January 2017 using keywords and/or medical subject headings for DIOS, NAFLD, NASH, hyperferritinemia, phlebotomy, and/or venesection, and/or iron depletion. For the Scopus database, only free text searches with truncations were carried out. We restricted the search to human studies and studies published in English language. Two reviewers (ARM and AG) independently screened the database search for titles and abstracts and retrieved relevant studies.
The full text articles of relevant studies were carefully reviewed to determine study eligibility separately by both authors. The bibliographies of the included articles, as well as review articles on the topic, were searched manually for any additional references.
Inclusion criteria
We included all studies that evaluated the impact of phlebotomy in patients with DIOS (as defined by the presence of increased hepatic iron concentration and/or body iron stores in the presence of at least one component of metabolic syndrome) and/or NAFLD. We included patients with DIOS and patients with NAFLD in the same analysis as they share several clinical features (e.g., association with metabolic syndrome, insulin resistance, disturbances of iron metabolism, presence of hepatic steatosis) and are likely part of the same disease spectrum. We included studies that reported pre-and postphlebotomy changes in the indices of insulin resistance such as serum insulin level, and the Homeostasis Model Assessment (HOMA) index, liver biochemical profile, NAFLD activity score, and liver histological parameters such as fibrosis, lobular inflammation, or steatosis. We also included studies that compared phlebotomy with LSC versus lifestyle changes alone in the management of patients with DIOS and/or NAFLD. Randomized control trials, prospective studies, and retrospective studies were all considered for determining study eligibility.
Exclusion criteria
We excluded abstracts, case reports, review articles, clinical guidelines, and consensus documents. We excluded studies that did not report the end-points needed for this meta-analysis. We also excluded studies that included subsets from previously published articles by the same authors. In case of two different studies reported from the same population, the data from the most recent study was selected for the meta-analysis. If the most recent study did not have the study end-point, then the older study was included for the analysis.
Analyses and end-points
We evaluated the effect of phlebotomy compared to LSC alone among patients with DIOS and/or NAFLD on: (i) indices of insulin resistance (HOMA index and serum insulin level); (ii) liver enzymes (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]); (iii) body mass index (BMI); (iv) non-invasive markers of liver inflammation and/or fibrosis (NAFLD activity score or fibrosis score); and (v) liver histological changes (hepatocyte ballooning and inflammation). We also undertook a meta-analysis that included only randomized controlled trials (RCTs) to determine the effect of phlebotomy in patients with DIOS and/or NAFLD. Finally, as not all patients with DIOS have NAFLD, we carried out a subgroup analysis including only patients with "NAFLD and increased body iron stores".
Data extraction and quality assessment
Two reviewers (ARM and AG) independently extracted data from each study using a standardized data extraction sheet. The last name of the first author, year of publication, type of study (RCT or prospective study), mean age and sex of the study participants, number of sessions of phlebotomy, and presence or absence of a control group were recorded. We also extracted data on serum ferritin, transferrin saturation, body mass index (BMI), serum insulin level and HOMA index, alanine transaminase (ALT), aspartate transaminase (AST), pre-phlebotomy and post-phlebotomy, whenever available. The results were then cross-checked by the other reviewer. Minor disparities in extracted data between the two authors were resolved by discussion. We contacted the authors of the studies by email whenever additional information was necessary. We used the Cochrane Collaboration tool to assess risk of bias for the RCTs included in the study (see Appendix S1). We also assessed reporting bias using funnel plots. Discrepancies between the two authors were resolved by discussion.
Statistical analysis
Pooled weighted analysis was carried out for each variable of interest and presented as delta means (change in the mean value from pre-phlebotomy to post-phlebotomy). We used Review Manager 5.3 software (The Cochrane Collaboration, Oxford, UK) to perform the meta-analysis of studies that compared phlebotomy to LSC alone. We used the inverse variance method to estimate the weighted mean difference (MD) in the variables between the treatment and control group. We assessed heterogeneity by means of a χ 2 -test (Cochran Q statistic) and quantified this with the I 2 statistic. I 2 was used to evaluate the level of heterogeneity, assigning the categories low, moderate, and high to values of 25%, 50%, and 75%, respectively. The fixed effects model was used for the meta-analysis, however, if there was significant heterogeneity, I
2 > 50%, we used a random-effects model. Additionally, in case of significant heterogeneity, we undertook subgroup analyses to explore the heterogeneity. We calculated the effect size of the intervention and reported results by the two well-known and accepted effect size estimates, namely the Cohen's d (r statistic) and Hedges' g statistic. 18 The pooled weighted standard deviations were calculated to determine the effect size.
RESULTS
Selection of studies
T HE SEARCH OF databases yielded 467 references ( Fig. 1 ). Among the 467 references in the databases, there were 257 studies after removal of repeat articles. We excluded 235 articles on title and abstract including 90 review articles, 26 case series or case reports, 23 letters to the editor, comments, or updates, 25 articles on basic sciences, and 71 studies unrelated to treatment. We retrieved 22 full text articles to assess for eligibility. We excluded 13 articles; 4 had no data, 5 had different end-points, and different intervention was applied in 4 studies. We included 9 studies for our systematic review. 3, [19] [20] [21] [22] [23] [24] [25] [26] There was full agreement among the reviewers regarding study selection for the analysis.
In the nine studies included in the systematic review, there were a total of 820 patients, of which 427 underwent phlebotomy with counseling regarding LSC, and 393 received LSC counseling alone. The patient and study characteristics are provided in Table 1 . Three of the nine studies were RCTs, 3, 25, 26 three were cohort studies with control groups, 20, 22, 23 and three were uncontrolled prospective observational studies. 19, 21, 24 Liver biopsy was carried out in all patients in three studies 21, 24, 25 and a majority of patients (~80%) had liver biopsy in an additional two studies. 22, 23 The proportion of patients with NASH versus NAFLD varied in these studies. In the other four studies, the diagnosis of NAFLD was made on the basis of risk factors for fatty liver, exclusion of other causes of elevated liver enzymes, and an echogenic liver on ultrasound. 3, 19, 20, 26 Five studies included only patients with hyperferritinemia, 3, [20] [21] [22] 25 whereas the remaining four studies included patients with normal or elevated serum ferritin levels. 19, 23, 24, 26 One study was not used for all the statistical analyses, 22 as this study included some patients that overlapped with another study from the same author (L. Valenti, personal communication). 23 Pooled weighted analysis to determine the effect of phlebotomy in patients with DIOS and/or NAFLD Eight studies with 792 patients (363 underwent phlebotomy and 329 were controls) with DIOS and/or NAFLD were included in the pooled weighted analysis. 3, [19] [20] [21] [22] [24] [25] [26] Neither the HOMA index (delta mean = À0.38; P = 0.17) nor the serum insulin level (delta mean = À1.2 mU/L; P = 0.15) were significantly altered by phlebotomy. There was a modest decrease in the mean serum ALT level by 15.8 IU/L (P = 0.01) in the group of patients who underwent phlebotomy.
Meta-analysis of all studies comparing phlebotomy versus LSC alone in patients with DIOS and/or NAFLD
We included five studies with 626 patients (303 in phlebotomy group and 323 in the control group) in this meta-analysis. 3, 20, 23, 25, 26 All five studies compared phlebotomy with LSC versus LSC alone in patients with DIOS and/or NAFLD. Three of the studies were prospective randomized controlled trials; 3, 25, 26 one was a propensity Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow chart of the selection of published works to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. 
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score-adjusted observational study, 23 and the other was a retrospective cohort study. 20 One RCT 25 and the observational study 23 were carried out in Italy at different time periods and did not have overlapping patients.
Markers of insulin resistance
Meta-analysis of studies comparing phlebotomy to counseling regarding LSC did not show a significant change in the HOMA index (MD À0.6; confidence interval [CI], À1.7, 0.5; P = 0.3) or the serum insulin level (MD À0.8 mU/L; CI, À5.3, 3.7; P = 0.73), with phlebotomy as compared to LSC alone (Table 2, Fig. 2 ). There was high heterogeneity in this analysis. The funnel plot revealed no significant bias (see Appendix S1).
Serum ALT and AST level
Meta-analysis of studies comparing phlebotomy versus counseling regarding LSC showed a mild decrease in serum ALT in the phlebotomy group compared to the control group, with a mean difference of À6.62 IU/L (CI, À11, À2.1; P < 0.01), but the effect size as determined by Cohen's d 0.15 (r statistic, 0.07) and Hedges' g 0.15, was very small. There was no significant improvement in AST in patients treated with phlebotomy compared to the control group (MD À0.66 IU/L; CI, À3.2, 1.8; P = 0.6). There was mild heterogeneity in the analysis (Table 2 , Fig. 3 ). The funnel plot revealed no significant bias (see Appendix S1).
Body mass index
Meta-analysis of studies comparing phlebotomy to counseling regarding LSC showed a mild but significant increase in the mean BMI in patients who were treated with phlebotomy compared to patients who received only LSC (MD 0.38 kg/m 2 ; CI, 0.01, 0.74; P = 0.04). There was no heterogeneity in the analysis (i 2 = 0%) (Fig. 4) . Funnel plot revealed no publication bias (see Appendix S1).
Meta-analysis of RCTs comparing phlebotomy versus LSC alone in patients with DIOS and/or NAFLD
We included three RCTs in this analysis. 3, 25, 26 One was undertaken in Italy, one in Australia, and one in France. A total of 379 patients (199 in phlebotomy group and 180 in the control group) were included in this analysis. The quality of the individual studies is provided in Figure S1 .
Our meta-analysis of studies comparing phlebotomy to counseling regarding LSC did not show a significant improvement in the HOMA index (MD À0.4; CI, À1.9, 1.1; P = 0.61) or serum insulin level (MD 1.7 mU/L; CI, À0.66, 4.1; P = 0.16) in patients who underwent phlebotomy as compared to LSC alone. Similarly, there was no significant improvement in the serum ALT level (MD À5.2 IU/L; CI, À10.7, 0.33; P = 0.07) or AST level (MD À0.47 IU/L; CI, À3.6, 2.7; P = 0.77). There was no significant change in the mean BMI among the two groups (MD 0.37 kg/m 2 ; CI, À0.57, 1.3; P = 0.45). There was mild to moderate heterogeneity in this analysis. The funnel plot revealed no significant bias.
Subgroup analysis Phlebotomy in patients with NAFLD and hyperferritinemia
Because not all patients with DIOS have NAFLD, and not all patients with NAFLD have increased body iron stores, we carried out a meta-analysis examining the effect of phlebotomy specifically in patients with NAFLD and hyperferritinemia. 3, 22, 25, 26 Four studies were included, three of which were prospective RCTs, 3, 25, 26 and a fourth, prospective case-control study. 22 A total of 348 patients (185 in phlebotomy group and 163 in control group) were included in this analysis.
The meta-analysis of studies comparing phlebotomy to counseling regarding LSC in NAFLD patients with Table 3 ). The funnel plot revealed no publication bias.
Effect of phlebotomy on liver histological parameters
Two studies evaluated the effect of phlebotomy on liver histological changes (Table 4) . 24, 25 One was an RCT 25 and the other was a phase II prospective study. 24 The primary end-point in both studies was improvement in liver histology as defined by the NAFLD activity score (NAS). 24, 25 Although both studies showed statistically significant improvement in the NAS with phlebotomy, there was no significant improvement in the individual components of the NAS, such as hepatic inflammation, ballooning, or fibrosis.
Two RCTs compared the effect of phlebotomy with LSC alone on non-invasive markers of liver steatosis and fibrosis: the fatty liver index and fibrosis-4 score in one RCT, 3 and hepatic steatosis grade quantified by magnetic resonance imaging in the other. 26 Both studies reported no benefit of phlebotomy over LSC alone in the improvement of liver steatosis or fibrosis as determined by the non-invasive markers (Table 4) .
DISCUSSION
I
RON HAS BEEN implicated in the pathogenesis of insulin resistance and several clinical trials have assessed the effects of iron depletion on indices of insulin resistance, such as the HOMA index and insulin sensitivity index, serum ALT, and liver histology in NAFLD. However, these studies have yielded inconsistent results. 3, [19] [20] [21] [22] [23] [24] [25] [26] While the initial uncontrolled series suggested a beneficial effect with phlebotomy in patients with DIOS and NAFLD, more recent RCTs have not shown a beneficial effect. 3, 26 Our pooled analysis of all studies -prospective uncontrolled observational series, prospective controlled studies, and RCTs -showed no significant improvement in HOMA index or serum insulin level with phlebotomy, and a mild improvement in serum ALT level. Although serum ALT levels significantly decreased with phlebotomy, conclusions cannot be drawn from these findings alone, as some of the studies included in the pooled analysis were uncontrolled studies, which are prone to bias. In fact, a previous study reported a statistically significant decrease in the pooled estimates of serum ALT among patients in the placebo arms of RCTs in patients with NAFLD. 27 Thus, to overcome this limitation, we carried out a meta-analysis of controlled studies that compared phlebotomy with LSC counseling alone in patients with DIOS and/or NAFLD.
In this meta-analysis of controlled trials comparing phlebotomy to LSC alone in patients with DIOS and/or NAFLD, we found: (i) no significant improvement in the indices of insulin resistance such as the HOMA index or Figure 4 Forest plot comparing iron depletion to lifestyle changes alone in the change in body mass index (BMI) in patients with dysmetabolic iron overload syndrome and/or and non-alcoholic fatty liver disease. serum insulin level with phlebotomy compared to LSC alone; (ii) mild improvement in serum ALT with phlebotomy but with very small effect size, and no improvement in AST; and (iii) an increase in BMI in patients who received phlebotomy compared to LSC alone. Additionally, even in the subgroup of patients with NAFLD and hyperferritinemia, there was no significant improvement in the indices of insulin resistance or liver enzymes with phlebotomy.
Our meta-analysis of all controlled studies shows that the indices of insulin resistance do not improve with phlebotomy. Although there was statistically significant improvement in serum ALT level with phlebotomy compared to LSC, this effect was mild as determined by the very small effect size (r statistic for serum ALT, 0.07). It may be argued that a small effect size does not necessarily mean a lack of efficacy 18 and, in the absence of an effective treatment for NAFLD, with phlebotomy being a relatively simple, safe, and inexpensive procedure, it is worth further consideration. However, even this small beneficial effect on serum ALT with phlebotomy disappeared when only the RCTs were analyzed. Additionally and importantly, none of the studies included in our systematic review showed a significant improvement in lobular inflammation or hepatocyte ballooning with phlebotomy. The three RCTs did not show a significant change in liver histology or non-invasive markers of liver injury with phlebotomy on an intention to treat analysis. 3, 25, 26 Based on the results of our meta-analysis, phlebotomy cannot be recommended as a treatment option in patients with DIOS and NAFLD.
Although we believe that these data are insufficient to recommend phlebotomy as routine treatment for DIOS or NAFLD, the results are intriguing nonetheless, in that some of the data are reminiscent of the results of the numerous phlebotomy trials in chronic hepatitis C infection done in the 1990s. [28] [29] [30] [31] [32] Taken together, these observations suggest that iron reduction may modulate hepatic inflammation. The mechanism of this effect and its relationship to the underlying cause of the inflammation is an important question for future research. Like NAFLD, chronic hepatitis C infection is associated with insulin resistance. 33 There are limited data showing improvement in insulin sensitivity with phlebotomy in subjects with diabetes without overt NAFLD, 34 suggesting that modulation of insulin sensitivity by iron reduction could be a common mechanism in all of these conditions, but our findings regarding the lack of an effect of phlebotomy on indices of insulin resistance do not support this premise. On the contrary, our meta-analysis revealed that patients treated with LSC alone had more significant weight loss compared to patients who received phlebotomy. In fact, Laine et al. showed in their RCT that patients who were treated with phlebotomy gained weight over the course of the study, which led to worsening of certain indices of insulin resistance in their study. 3 It is possible that the true effect of phlebotomy may be masked or negated by concomitant weight gain in patients who were treated with phlebotomy. In these studies, weight gain occurred despite the fact that patients in the phlebotomy group were given the same counseling regarding LSC that was provided to the control group. As there is no reason to believe that phlebotomy per se caused the weight gain, we speculate that patients who underwent phlebotomy were less motivated to lose weight because they perceived that phlebotomy was sufficient treatment for their underlying metabolic condition. It would be interesting to know whether there is an additive benefit of phlebotomy in those patients who are able to lose weight, but we currently have no data addressing this possibility.
Despite these less than compelling results, it has been suggested that phlebotomy deserves a second look in the select group of patients with NAFLD and hyperferritinemia. Adams et al. found no improvement in indices of insulin resistance in the subgroup of patients with NAFLD and hyperferritinemia, but the sample size was small. 26 In the study by Laine et al., phlebotomy did not result in an improvement in the indices of insulin resistance, but improved serum ALT level. 3 However, only 59% of patients in their study had NAFLD. In our subgroup analysis of 348 patients with NAFLD and elevated ferritin levels (excluding patients with DIOS without evidence of liver disease, and excluding patients with NAFLD but without elevated body iron stores), we observed no improvement in HOMA index, insulin level, or serum ALT or AST levels. Although the data at present do not support a strategy of phlebotomy for all patients with NAFLD, it is possible that there may be subgroups of NAFLD patients based on the pattern of iron deposition or stage of disease who might benefit from phlebotomy (i.e., those with hepatocellular iron deposition versus reticuloendothelial iron deposition, or early versus advanced fibrosis), but this is unknown at present. None of the studies included in our report differentiated NAFLD patients with hyperferritinemia based on the pattern of iron deposition. Indeed, liver biopsies were not carried out in most of the studies we reviewed, which precludes assessment of the impact of iron distribution. However, it must be noted that studies that have evaluated the effect of parenchymal versus non-parenchymal hepatic iron deposition on the degree of liver histological injury have yielded conflicting results [35] [36] [37] and there is no causality established so far. It should also be pointed out that all of the studies included in our analysis excluded patients with hereditary hemochromatosis (C282Y/C282Y or C282Y/H63D) HFE gene mutations. Whether phlebotomy would have differential effects in NAFLD patients with non-hemochromatosis-associated HFE genotypes, such as simple heterozygosity for C282Y, compared to patients with no HFE mutations, is unknown. Likewise, it is certainly possible that phlebotomy may have a beneficial effect in patients with NASH or liver fibrosis compared to patients with NAFLD without fibrosis. Because the available studies included varying proportions of patients with NASH versus NAFLD, a benefit of phlebotomy in patients with hepatic inflammation or fibrosis cannot be excluded. As pointed out in the American Association for the Study of Liver Diseases practice guidelines on NAFLD, treatments aimed at mitigating liver disease should be limited to patients with NASH, as patients with NAFLD without steatohepatitis have an excellent prognosis from the liver standpoint. 38 Finally, except for the study by Valenti et al., who evaluated liver histological changes at a follow-up of 2 years, all other studies had a short followup period of 6 months or less. The duration of follow-up may have affected the degree of histological changes with phlebotomy. Future studies, if contemplated, should probably be a controlled prospective trial of phlebotomy in an adequately powered group of NASH patients with hyperferritinemia with adequate length of follow-up, to definitively assess the efficacy of phlebotomy in NASH.
A previous meta-analysis found that phlebotomy was associated with significant decreases in HOMA index, serum ALT, and serum triglyceride levels in patients with NAFLD. 39 However, this meta-analysis included only four studies, two of which were undertaken in the same region and had an overlapping patient population. 22, 23 In addition, not all patients in the included studies had evidence of iron overload. 23 We excluded studies with overlapping patient populations, and all patients included in our main analysis had evidence of DIOS. In addition, our metaanalysis includes the largest RCT carried out to date on the impact of phlebotomy in patients with DIOS. 3 A limitation of our meta-analysis is the presence of significant heterogeneity in some of the results. Subgroup analysis decreased the heterogeneity on some parameters but not all. However, we used the random effects model for parameters with high heterogeneity to account for both within-study and between-study variance.
CONCLUSION
P
HLEBOTOMY IS NOT associated with a significant improvement in the indices of insulin resistance in patients with DIOS and/or NAFLD compared to counseling regarding LSC alone. Phlebotomy results in a mild but significant decrease in serum ALT with a very small effect size, and no improvement in AST. Even in the subgroup of patients with NAFLD and hyperferritinemia, phlebotomy does not improve insulin resistance or liver enzymes. Finally, phlebotomy has not been shown to have a significant benefit in improving liver inflammation or fibrosis. The use of phlebotomy cannot be recommended as a treatment strategy in all patients with DIOS and/or NAFLD.
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